GRCE
Grace Therapeutics, Inc.
NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY
$2.10
+0.00% today
Updated 2026-04-29
Market cap
$33.42M
P/E ratio
—
P/S ratio
197.75x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$2 – $5
Volume
0.8M
Grace Therapeutics, Inc. (GRCE) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$2.10
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.